Wire · opportunities
FDA Grants Accelerated Approval to Neladalkib for Previously Treated ALK-Positive NSCLC
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 17 November 2026 · Fusion42 review
The FDA granted accelerated approval to neladalkib for adults with advanced ALK-positive non-small cell lung cancer previously treated with specific ALK inhibitors and platinum chemotherapy. The approval is based on durable response data from the ALKOVE-1 trial, with ongoing confirmatory studies required.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.
◆ ◆ The Wire takeaway
Biotech founders in lung cancer should start structuring their clinical plans around accelerated approvals that hinge on durable responses in targeted subpopulations. This approval opens a narrow but clear path to market that demands precise patient selection and ongoing safety vigilance.
◆ Coverage
2 sources · 17 Nov 2026
◆ Related on Wire
◆ Topics